Mission Bio Leadership

Charlie Silver

Charlie Silver


Prior to Mission Bio, Charlie spent 15 years commercializing next-generation hardware technology and scientific instrumentation at companies including Agilent, Novelx, Glimmerglass Networks, and Princeton Optronics. Charlie was engineering director, product manager, and first employee at Novelx, a Scanning Electron Microscope start-up that was acquired by Agilent in 2009. He holds a B.A. in physics from Columbia University, an M.S. in physics from the University of Wisconsin at Madison, and a dual MBA from Berkeley/Haas and Columbia.

Dennis Eastburn, Ph.D.

Dennis Eastburn, Ph.D.


Dennis has 17 years of experience in life science research and R&D program management. As a senior researcher in the Abate Lab at UCSF, Dennis led development of the core IP that enables Mission Bio’s single-cell approach and secured the early stage funding that launched the company. Dennis holds a B.S. in molecular biology from the University of Texas at Austin and a Ph.D. in molecular, cellular and developmental biology from the University of Colorado at Boulder. Prior to his stay in the Abate lab, he completed an NIH funded postdoctoral fellowship in cell biology at UCSF.

Adam Sciambi, Ph.D.

Adam Sciambi, Ph.D.

Engineering Director

Adam leads Mission Bio’s microfluidics design and systems development. His expertise is in microfabrication and scientific instrumentation development. He holds a B.S. in physics from Stanford, and an M.S. and Ph.D. in applied physics from Stanford. He also served as a postdoctoral scholar at UCSF, where his research played a key role in Mission Bio’s microfluidics platform development.

Mission Bio Board

Adam Abate

PhD, is a physicist and bioengineer with a research focus on developing new tools for high-throughput biology. He is a co-inventor of droplet-based genomic cytometry and co-founder of Mission Bio. He is a faculty member at UCSF and part of the California Institute for Quantitative Biosciences (QB3) and a recent winner of the NSF CAREER and NIH New Innovator Awards. His lab continues to develop new technologies for biomedical research, protein engineering, and synthetic biology.

Paul R. Billings

MD, PhD, FACP, FACMG is a physician, researcher in immunology and biomedicine, corporate executive and entrepreneur.  He currently serves as a consultant to several public biotechnology companies and as a director in the for-profit and non-for-profit sectors.  His interests are in enabling the development of global precision medicine through basic research and innovation.

William Hyun

MS, PhD is the Director of the Laboratory for Advanced Cytometry at the University of California, San Francisco (UCSF). He leverages over 25 years of translational and clinical research experience into founder, investor and advisor roles for several biotechnology companies and life science investment groups. At UCSF, he helped build the world’s largest academic cytometry facility and continues to design and build next generation cell sorters, commercial flow cytometers and confocal microscopes

Maneesh Jain

Maneesh Jain PhD is an experienced entrepreneur and executive. He has successfully built four startup companies – ParAllele, Auriphex, Ion Torrent and Butterfly – from inception, to financing (over $200M raised in total), through acquisition by mid-size firms and to commercial success. Maneesh has also served as an executive advisor to several life science companies including Cellular Research (acquired by BD 2015), Counsyl, Inscopix, Invitae (IPO 2015).

Brock Siegel

PhD, is an investor and advisor in seed-stage life science investment groups including BioInflexion Point, Life Science Angels, NEW Capital Fund LP, and QB3 Mission Bay Capital Fund. He serves on the Board of Directors of Rapid Diagnostek Inc and the Addario Lung Cancer Medical Institute, and on the Advisory Boards of Ruubix Diagnostics Inc and Moleculo Sequencing Inc. Brock has been a senior executive with Millipore, BioSearch, Applied Biosystems, Solexa, Illumina, Complete Genomics and Moleculo.

There's More To Know. Get In Touch.

If you are interested in working together, send us an inquiry and we will get back to you as soon as we can!
Contact Us